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A B S T R A C T
The epizootic prion disease of cattle, bovine spongiform encephalopathy (BSE), causes variant Creutzfeldt-Jakob
disease (vCJD) in humans following dietary exposure. While it is assumed that all cases of vCJD attributed to a
dietary aetiology are related to cattle BSE, sheep and goats are susceptible to experimental oral challenge with
cattle BSE prions and farmed animals in the UK were undoubtedly exposed to BSE-contaminated meat and bone
meal during the late 1980s and early 1990s. Although no natural ﬁeld cases of sheep BSE have been identiﬁed, it
cannot be excluded that some BSE-infected sheep might have entered the European human food chain.
Evaluation of the zoonotic potential of sheep BSE prions has been addressed by examining the transmission
properties of experimental brain isolates in transgenic mice that express human prion protein, however to-date
there have been relatively few studies. Here we report that serial passage of experimental sheep BSE prions in
transgenic mice expressing human prion protein with methionine at residue 129 produces the vCJD phenotype
that mirrors that seen when the same mice are challenged with vCJD prions from patient brain. These ﬁndings
are congruent with those reported previously by another laboratory, and thereby strongly reinforce the view that
sheep BSE prions could have acted as a causal agent of vCJD within Europe.
1. Introduction
Bovine spongiform encephalopathy (BSE) is an epizootic transmis-
sible spongiform encephalopathy (TSE) or prion disease of domestic
cattle and causes variant Creutzfeldt-Jakob disease (vCJD) in humans
following dietary exposure [1–4]. Whilst the incidence of vCJD in the
UK has been in decline for over a decade and the risk of new dietary
exposure to BSE prions is remote, the majority of the UK population
may have been exposed during the late 1980s and early 1990s. Because
the interval between BSE prion exposure and development of clinical
signs of vCJD may be decades [5–7] there is considerable uncertainty in
knowing how many people may have been infected. Presently it is es-
timated that 1 in 2000 of the UK population may have subclinical prion
infection [8] however the proportion of infected individuals that may
go on to develop clinical disease, rather than remaining as asympto-
matic carriers, is unknown [9].
Due to the inherent limitations of public health and epidemiological
studies to address key uncertainties related to the nature and extent of
BSE-related human prion disease in the UK, surrogate methods have
been developed to evaluate the relative pathogenicity of animal prions
for humans [10]. One major approach involves the experimental
transmission of disease by inoculation of homogenised brain tissue from
aﬀected animals into transgenic mice overexpressing one or other of the
two common polymorphic forms of the human prion protein (PrP) with
either methionine (M) or valine (V) at residue 129 on a mouse PrP null
background. Experimental transmission of BSE and vCJD prions to such
mice has demonstrated the critical role of residue 129 polymorphism in
determining susceptibility, incubation time and pathological phenotype
(for review see Ref. [11]). These eﬀects relate not only to the im-
portance of homologous protein interactions in prion propagation
[5,12–14] but also to the preferential propagation of diﬀerent prion
strains by PrP with diﬀerent primary structures via conformational
selection [5,11,13,14]. Findings from these models indicate that pri-
mary and secondary human infection with BSE prions may result in
sporadic CJD-like or novel phenotypes in addition to vCJD, depending
on the PrP genotype of the prion source and the recipient [4,11,15].
Because prion strains can adapt and mutate on passage in new
species, and also within species as a result of PrP polymorphisms and
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other genetic factors, the evaluation of their risks to public health is
complex [9,11,14,16–19]. Transgenic mouse models have therefore
also been used to evaluate the zoonotic potential of prions generated by
experimental transmission of cattle BSE prions to other species. Sheep
and goats expressing diﬀerent natural polymorphic variants of ovine or
caprine PrP can be readily infected with BSE prions via the oral route
(for recent review see Ref. [20]) and farmed animals were undoubtedly
exposed to BSE-contaminated meat and bone meal. Discriminatory
testing of all small ruminant TSE cases has been mandatory at EU level
since 2005 (EC reg 999/2001 as amended, 36/2005) and while ﬁeld
cases of BSE-infected goats have been recognised [21,22] retrospective
studies within the UK have failed to identify any BSE-like cases in sheep
[23,24]. Nevertheless it cannot be ruled out that some TSE-aﬀected
sheep assigned at the time as cases of natural scrapie may in fact have
been infected with BSE prions [25], particularly early in the epidemic
before the feed ban to prohibit the inclusion of mammalian protein in
animal feedstuﬀs was fully eﬀective.
Two studies have previously concluded that experimental sheep BSE
prions may propagate more eﬃciently than cattle BSE prions in trans-
genic mice expressing human PrP 129M [26,27] and one of these stu-
dies convincingly established that sheep and goat BSE prions trans-
mitted a molecular and neuropathological phenotype congruent with
transmission of vCJD prions in the same mice [27]. These data strongly
suggest that small ruminant BSE prions might act as a causal agent of
vCJD [27]. Given the potential relevance of these ﬁndings to under-
standing the aetiology of vCJD in the UK (and as part of a larger
transmission series evaluating the zoonotic potential of natural ﬁeld
cases of classical and atypical scrapie from sheep), we have also chal-
lenged our transgenic mice with isolates of experimental sheep BSE
prions [28]. In contrast to the ﬁndings of others [26,27], we observed a
very low eﬃciency of transmission of experimental ovine BSE prions to
mice expressing human PrP 129M and identiﬁed only a single sub-
clinically infected mouse with detectable disease-related PrP (PrPSc) in
brain [28]. Despite this low attack rate (the potential reasons for which
we have discussed previously [28]), we nevertheless considered it im-
portant to characterize the prion strain type that was generated from
this transmission to inform upon whether vCJD prions or a novel prion
strain type had propagated in our mice [28]. Here we now report the
results from secondary passage of this isolate in further transgenic mice
and in wild-type mice in comparison to the transmission properties of
vCJD prions from patient brain to the same lines of mice.
2. Materials and methods
2.1. Biosafety
Work with prion-infected samples was conducted in microbiological
containment level 3 or level 2 facilities with strict adherence to safety
protocols.
2.2. Research governance
Storage and biochemical analysis of human tissue samples and
transmission studies to mice were performed with informed consent
from patients or relatives under approval from the Local Research
Ethics Committee of UCL Institute of Neurology/National Hospital for
Neurology and Neurosurgery and the code of practice speciﬁed in the
Human Tissue Authority licence held by UCL Institute of Neurology.
Work with animals was performed under licence granted by the UK
Home Oﬃce (Project Licences 70/6454 and 70/7274) and conformed
to University College London institutional and ARRIVE guidelines.
2.3. Transgenic and wild-type mice
Transgenic mice homozygous for a human PrP 129V transgene array
and murine PrP null alleles (Prnpo/o), designated Tg(HuPrP129V+/
+Prnpo/o)-152c mice (129VV Tg152c mice), or homozygous for a
human PrP 129M transgene array and murine PrP null alleles (Prnpo/o),
designated Tg(HuPrP129M+/+Prnpo/o)-35c mice (129MM Tg35c mice)
have been described previously [28–30] and are fully susceptible to
challenge with human prions. Both lines of mice have a congenic FVB/
N, mouse PrP null, background and were derived from 129MM Tg35
and 129VV Tg152 parental lines which have been used extensively by
us in previous human prion transmission studies [2,4,15,31,32].
129MM Tg35c and 129VV Tg152c overexpress human PrP in brain at
levels of 2- and 6-times that of pooled human brain, respectively. No
spontaneous generation of prion infection has ever been observed in the
parental (129MM Tg35 and 129VV Tg152) or the congenic (129MM
Tg35c and 129VV Tg152c) lines of mice at advanced old age (either
uninoculated groups of mice or recipients inoculated with vehicle only).
Inbred FVB/NHsd mice (genotype Prnpa) were supplied by Harlan, UK.
2.4. Source of 129MM Tg35c-passaged ovine BSE prions
Previously [28] we inoculated transgenic mice expressing human
PrP (129MM Tg35c mice and 129VV Tg152c mice) with an experi-
mental ovine BSE isolate (AHVLA SE1945/0032) that was obtained
after secondary-passage of cattle BSE prions in sheep homozygous for
ovine PrP with an ARQ genotype at codons 136, 154, 171 [33] (Fig. 1).
Immunohistochemical and immunoblot analyses of brain following
long post-inoculation survival periods identiﬁed a single subclinically
aﬀected 129MM Tg35c mouse that was culled 661 days post-inocula-
tion when the experiment was terminated (mouse ID 223157) [28]
(Fig. 1). PrPSc in the brain of this mouse showed a predominance of
diglycosylated PrP and appeared similar to type 4 PrPSc (which is pa-
thognomonic of vCJD [1,34]) however the ﬂorid PrP plaques that
characterize the propagation of the vCJD prion strain in humans [35] or
transgenic mice [4] were not observed [28]. To deﬁne the prion strain
type propagated in this transmission, brain inoculum from mouse ID
223157 was prepared by diluting 10% (w/v) brain homogenate to 1%
(w/v) with Dulbecco's sterile phosphate buﬀered saline lacking Ca2+
and Mg2+ ions (D-PBS). Aliquots were stored frozen before inoculation
into mice as described below.
2.5. Transmission of prions from mouse ID 223157
Mice (female, aged 6–8 weeks) were randomly assigned to experi-
mental groups of 20 and anaesthetized with a mixture of halothane and
O2, and intracerebrally inoculated into the right parietal lobe with 30 μl
of 1% (w/v) brain homogenate from mouse ID 223157 prepared in D-
PBS as described above. Thereafter all mice were examined daily for
early indicators of clinical prion disease including piloerection, sus-
tained erect ears, intermittent generalised tremor, unsustained hunched
posture, rigid tail, mild loss of coordination, and clasping hind legs
when lifted by the tail [30]. Deﬁnite diagnosis of clinical prion disease
(triggering experimental end point) was reached if mice exhibited any
two early indicator signs in addition to one conﬁrmatory sign, or any
two conﬁrmatory signs. The conﬁrmatory signs included ataxia, im-
pairment of righting reﬂex, dragging of hind limbs, sustained hunched
posture, or signiﬁcant abnormal breathing [30]. Clinical diagnosis can
be confounded by non-speciﬁc conditions which develop in mice as
they age and there is considerable variation in the mean lifespans of
diﬀerent lines of transgenic mice and the onset of ageing artefacts. In
this transmission series, we limited these confounding eﬀects by elec-
tively culling mice after a deﬁned post-inoculation period of 700 days.
Such elective culling reduces the occurrence of ‘found dead’ mice that
die of old age, in which brain tissue can undergo autolytic deterioration
which precludes immunohistochemistry (IHC) analyses. At post-
mortem, brains from inoculated mice were removed, divided sagittally
with half frozen and half ﬁxed in formol-saline.
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2.6. Transmission of vCJD prions from patient brain
For more than twenty years we have conducted vCJD prion trans-
missions from the brain of multiple patients with neuropathologically
conﬁrmed vCJD. Initial studies used 129VV Tg152, 129MM Tg35 and
wild-type FVB/N mice [2,4,15,31,32] while later studies have used
129MM Tg35c and 129VV Tg152c mice [28,29] (and our unpublished
data). In these transmissions 30 μl of 1% (w/v) brain homogenate (ty-
pically frontal cortex grey matter) prepared in sterile phosphate buf-
fered saline was intracerebrally inoculated into mice after which mice
were observed over their lifespan, or electively culled beyond 600 days
post-inoculation. In the present study we have used these multiple
historical vCJD prion transmissions as a control reference series and
have used transmission data and mouse brain samples from one of these
(vCJD patient brain isolate I336) to exemplify the distinguishing mo-
lecular and neuropathological phenotypes that are seen in the mice.
Frozen brain homogenates and ﬁxed brain samples from mice in these
transmissions were re-analysed together with the new brain samples
generated from the transmissions of brain inoculum from mouse ID
223157.
2.7. Immunoblotting
Frozen brain samples from mice or vCJD patients were prepared as
10% (w/v) homogenates in D-PBS using a tissue grinder [36]. Human
or mouse brain homogenates were analysed by proteinase K digestion
(50 or 100 μg/ml ﬁnal protease concentration, 1 h, 37 °C) and immuno-
blotting using high sensitivity enhanced chemiluminescence as de-
scribed previously [36,37]. Gels were calibrated using the Seeblue Pre-
stained Protein Standard from Invitrogen. Detection of human PrP was
performed using anti-PrP monoclonal antibody 3F4 [38] and the de-
tection of mouse PrP was performed using ICSM 35 (D-Gen Ltd.,
London). Molecular strain typing of human PrPSc was performed using
reference cases of human prion disease of known PrPSc type using the
London classiﬁcation [34]. Transgenic or wild-type mouse brain
homogenates that were scored as negative for PrPSc after analysis of
10 μl 10% (w/v) brain homogenate were re-analysed by sodium phos-
photungstic acid (NaPTA) precipitation of PrPSc from 250 μl of 10% (w/
v) brain homogenate as described previously [37].
2.8. Neuropathology and immunohistochemistry
Brain ﬁxed in 10% buﬀered formol-saline was immersed in 98%
formic acid for 1 h and then embedded in paraﬃn wax. Serial sections
(4 μm thick) were pre-treated by boiling for 10 min in a low ionic
strength buﬀer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate,
pH 7.8) before exposure to 98% formic acid for 5 min. Abnormal PrP
accumulation was detected using anti-PrP monoclonal antibody ICSM
35 (D-Gen Ltd., London) on an automated IHC staining machine
(Ventana Medical Systems Inc., Tucson, Arizona) using proprietary
secondary detection reagents (Ventana Medical Systems Inc.) before
development with 3′3 diaminobenzedine tetrachloride as the chro-
mogen [36]. Conventional methods were used for Harris haematoxylin
and eosin (H&E) staining. Positive controls for the staining technique
were used throughout. All slides were digitally scanned on a LEICA
SCN400 instrument, and images were captured from the LEICA slide-
path software and composed with Adobe Photoshop. Abnormal PrP
deposition in vCJD brain is distinguished by the presence of abundant
ﬂorid PrP plaques consisting of a round amyloid core surrounded by a
ring of spongiform vacuoles [35,36]. The vacuolation pattern that
Fig. 1. Summary of prion transmission rates to transgenic
or wild-type mice.
Mice were intracerebrally inoculated with 1% (w/v) brain
homogenate. Attack rates report the total of clinically af-
fected and subclinically infected mice as a proportion of the
number of inoculated mice after prolonged post-inoculation
periods. The type of PrPSc observed in the brain of aﬀected
mice is also reported. (A) Serial passage of cattle BSE prions
in sheep (homozygous for ovine PrP with an ARQ genotype
at codons 136, 154, 171) followed by transmission of sheep
BSE prions to transgenic mice homozygous for human PrP
with either methionine (M) or valine (V) at residue 129.
These transmissions identiﬁed a single subclinically in-
fected 129MM Tg35c mouse (ID 223157) that propagated a
diglycosylated dominant PrPSc type in brain [28]. (B)
Transmission of prions from mouse ID 223157 to further
transgenic mice and to wild-type FVB mice. (C) Primary
transmission of vCJD prions from patient brain (I336) to
transgenic mice and to wild-type FVB mice. Full details of
the transmissions shown in panels B and C are provided in
the Tables.
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characterises ﬂorid plaques is most clearly observed on H&E stained
sections [35,36].
3. Results and discussion
3.1. Summary of transmissions of vCJD prions to transgenic and wild-type
mice
Over the last twenty years we have transmitted vCJD prions from
multiple vCJD patient brain samples to transgenic mice expressing
human PrP and wild-type FVB/N mice. All of the vCJD isolates we have
examined behaved consistently in each line of mice with prion trans-
mission properties that readily distinguish the vCJD prion strain from
all other forms of human prion disease. In the present study we have
used these multiple historical vCJD prion transmissions as a control
reference series with which to compare our new transmissions and have
used transmission data and mouse brain samples from one of these
(vCJD patient brain isolate I336) (Fig. 1, Table 1) to exemplify the
characteristic molecular and neuropathological phenotypes that are
seen in the mice. In all of these studies (referenced below) we have
never observed the spontaneous generation of prion infection in control
groups of either transgenic or wild-type mice.
Challenge of our transgenic mice expressing human PrP 129M with
vCJD prions from patient brain results in a high incidence of prion
infection and faithful propagation of type 4 PrPSc (London classiﬁca-
tion; Figs. 1 and 2, Table 1) [4,15,29,31,39] which is pathognomonic of
the vCJD prion strain [1,34]. Propagation of type 4 PrPSc in these mice
is often accompanied by the key neuropathological hallmark of vCJD,
the presence of abundant ﬂorid PrP plaques, which are frequently seen
on a strong background of synaptic PrP deposition (Fig. 3)
[4,15,29,31,39].
Notably, although vCJD prions produce high attack rates of infec-
tion in human PrP 129M transgenic mice (typically 100%) many af-
fected mice do not develop clinical signs of prion disease and instead
remain subclinically infected to advanced old age [4,15,29,31,39]. This
lack of clinical end point has been observed with numerous vCJD brain
isolates that we have examined, including those with very high levels of
type 4 PrPSc, and indeed, even with vCJD isolates that produce a high
incidence of clinical prion disease the mean incubation periods are
close to the lifespan of the mice. For example, although vCJD brain
isolate I336 produced clinical prion disease in 11/12 inoculated
129MM Tg35c mice (which is the highest incidence we have so far
observed) the mean incubation period was 662 ± 12 days (Table 1).
Similar long mean incubation periods (around 500 days) for primary
transmission and secondary passage of vCJD prions have also been seen
by other researchers in Tg650 transgenic mice that express human PrP
129M in brain at 3-times higher levels than our 129MM Tg35c mice
[27,40]. This situation of prominent subclinical infection and highly
prolonged clinical incubation times has eﬀectively precluded our ability
to reliably estimate vCJD prion titre in human PrP 129M mice using
conventional serial dilution and incubation period methods [41]. As a
consequence of this situation, we have found that demonstration of
vCJD prion transmission to human PrP 129M mice is most reliably
determined by demonstrating the propagation of type 4 PrPSc in the
brain of inoculated recipients by immunoblotting rather than mea-
suring the incidence and timing of clinical prion disease [4,15,39,42].
Using this approach we have previously demonstrated the ability to
detect prion transmission from a vCJD peripheral tissue containing
PrPSc at a level 104.7-fold lower than in the brain of the same vCJD
patient and showed that propagating PrPSc in the brain of the recipient
mice can be detected at an early stage of brain pathogenesis, well before
abnormal PrP deposition becomes detectable by IHC [42]. While this
study ﬁrmly established that the presence of minute quantities of PrPSc
in vCJD tissues is indicative of the presence of infectious prions, it is
important to note that PrPSc concentration may only broadly inform
upon infectious prion titre as the majority of disease-related PrP present
in vCJD brain is degraded by proteinase K [43,44] and the proportional
contribution of classical PrPSc to total infectivity remains unclear [45].
Diﬃculties in accurately correlating levels of detectable protease-re-
sistant PrP with prion titre are well documented in other prion strain/
Table 1
Primary transmission of vCJD prions from patient brain to transgenic and wild-type mice.
Mouse line Clinical attack ratea Incubation period (days ± SEM) Total attack rateb Survival (days)c
129MM Tg35c 11/12 662 ± 12 12/12 548, 651–712 (11)
129VV Tg152c 1/12 719 8/12 460, 490, 517, 651–891 (9)d
FVB/N 6/8 342 ± 31 8/8 253, 260, 337, 355, 363, 403, 421, 426e
a All mice were inoculated with 30 μl of 1% (w/v) vCJD brain homogenate (code I336). Clinical attack rate is deﬁned as the total number of clinically aﬀected mice as a proportion of
the number of inoculated mice. Incubation periods are reported for clinically aﬀected mice in days; where n≥ 3 the mean ± SEM is reported otherwise individual incubation times are
given.
b Total attack rate is deﬁned as the total number of clinically aﬀected and subclinically infected mice as a proportion of the number of inoculated mice. Subclinical prion infection was
assessed by immunohistochemical examination of brain for abnormal PrP deposition and immunoblot analysis of brain homogenate for PrPSc.
c The interval between inoculation and culling (due to clinical prion disease, inter-current illness, senescence, or termination of the experiment) in days. Death dates of individual mice
are shown together with the range for mice surviving beyond 600 days with the number of mice in this range shown in parentheses.
d Unaﬀected Tg129VV Tg152c mice were culled at 460, 490, 517 and 687 days post-inoculation.
e Subclinically infected FVB mice were culled at 363 and 403 days post-inoculation.
Fig. 2. Molecular strain typing of vCJD prion transmissions from patient brain to trans-
genic mice. (A, B) Immunoblots of proteinase-K digested 10% (w/v) brain homogenates
from a vCJD patient brain or vCJD prion-inoculated transgenic mice analysed by en-
hanced chemiluminescence with anti-PrP monoclonal antibody 3F4. The volumes of
samples loaded were varied to give comparable levels of total PrP signal intensity in each
lane. (A) vCJD patient brain and a clinically aﬀected vCJD prion-inoculated 129MM
Tg35c mouse that was culled 664 days post-inoculation demonstrating faithful propaga-
tion of type 4 PrPSc (T4). (B) Lanes 1 and 2, vCJD prion-inoculated 129MM Tg35c mouse
brain from two clinically aﬀected mice (culled 688 and 664 days post inoculation)
showing propagation of type 4 PrPSc (T4) compared to brain from two subclinically in-
fected vCJD prion-inoculated 129VV Tg152c mice (culled 860 and 716 days post-in-
oculation) propagating type 5 PrPSc (T5). Immunohistochemical analyses of brain from
the same mice shown in panel B lanes 2 and 4 are presented in Fig. 3.
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host combinations [46] and indeed prion transmissions from tissues
with undetectable protease-resistant PrP have been reported [47,48].
In contrast to the eﬃciency with which vCJD prions infect human
PrP 129M mice, primary challenge of transgenic mice expressing
human PrP 129V is characterised by a substantial transmission barrier
with only a proportion of inoculated mice becoming infected (Table 1,
Fig. 1) [2,15,32,49]. As with human PrP 129M mice, subclinical in-
fection at advanced old age is a common feature of these transmissions.
Aﬀected vCJD-challenged human PrP 129V mice propagate a novel
prion strain associated with type 5 PrPSc (Fig. 2) [2,15,32] which shares
the same predominance of the diglycosylated PrP glycoform seen in
type 4 PrPSc but is distinguished by proteinase K digestion products of
greater molecular mass, indicative of a distinct PrPSc conformation
(Fig. 2) [2,15,32]. Propagation of type 5 PrPSc following primary
transmission of vCJD prions is generally associated with low levels of
pathological PrP deposition in brain when visualised by IHC. Abnormal
PrP deposition (when detected at primary transmission) is observed as
focal or patchy diﬀuse labelling mainly in the midbrain and brainstem
(Fig. 3) [2] and occasionally in some mice, as large non-ﬂorid PrP
plaques in the corpus callosum [32]. There is a notable absence of ﬂorid
PrP plaques even after secondary passage of type 5 PrPSc isolates in
further human PrP 129V mice [15]. As with human PrP 129M mice, the
most reliable way of assessing vCJD prion transmission rates in human
PrP 129V mice is through detection of PrPSc in the brain of inoculated
recipients following long clinically silent survival periods.
In wild-type FVB/N mice, vCJD prions from patient brain have a
high primary transmission rate, often resulting in clinical prion disease
in aﬀected mice, although incubation periods are prolonged (typically
in the range of 300–400 days) (Table 1, Fig. 1) [2,15,32,49]. In these
transmissions a distinctive diglycosylated PrP dominant PrPSc type is
propagated in brain (Fig. 4) which is identical to that seen after
transmission of cattle BSE prions to the same mice [2,15,32]. Abnormal
PrP deposition in aﬀected mice consists mainly of patchy diﬀuse and
granular deposits in the midbrain and brainstem with occasional small
PrP plaques, however ﬂorid PrP plaques are not observed (Fig. 4) [2].
The eﬃciency with which vCJD prions transmit infection to wild-type
FVB/N mice is remarkable and readily distinguishes the vCJD prion
strain from all alternative prion strains that are propagated in other
forms of human prion disease [2,15,32,49].
3.2. Transmission of 129MM Tg35c-passaged ovine BSE prions to
transgenic and wild-type mice
We generated brain inoculum from the single subclinically infected
ovine BSE-challenged 129MM Tg35c mouse (mouse ID 223157) from
our earlier study [28] (Fig. 1; see Materials and Methods) and in-
oculated this intracerebrally into further groups of 129MM Tg35c,
129VV Tg152c and FVB/N mice. The transmission properties of prions
from this isolate in both transgenic mice and wild-type mice were en-
tirely consistent with those of vCJD prions (Fig. 1, Table 2).
In 129MM Tg35c mice we observed a high attack rate of infection
(17 of 19 inoculated mice; Table 2) and the propagation of type 4 PrPSc
(Fig. 5) in all aﬀected mice. In mice in which abundant type 4 PrPSc was
detected in brain homogenate (11 of 17 aﬀected mice) numerous ﬂorid
PrP plaques were observed in the cortex (Fig. 6). Although the in-
cidence of clinical prion disease and the overall intensity of PrP de-
position in brain were lower than seen after the transmission of vCJD
prions from patient brain isolate I336 which we used as a comparator,
this was well within the range we have observed from transmission of
other vCJD prion isolates and probably simply reﬂects a lower prion
titre in the inoculum. In this regard the PrPSc concentration in the brain
of mouse ID 223157 was about 5% of that typically seen in vCJD pa-
tient brain homogenates [28]. As mentioned above, the frequent pre-
sence of subclinical infection in vCJD prion-inoculated human PrP
Fig. 3. Neuropathological analyses of vCJD prion trans-
missions from patient brain to transgenic mice. Panels A, C,
and E, a clinically aﬀected vCJD prion-inoculated 129MM
Tg35c mouse propagating type 4 PrPSc (see Fig. 2B, lane 2)
culled 664 days post-inoculation. Panels B, D, and F, a
subclinically infected vCJD prion-inoculated 129VV
Tg152c mouse propagating type 5 PrPSc (see Fig. 2B, lane 4)
culled 716 days post-inoculation. (A, B) Sagittal sections of
whole brain. (C–F) Higher power magniﬁcation of the
boxed regions shown in panels A and B; (C) cortex, (D)
midbrain. (A–D) Abnormal PrP immunoreactivity stained
with anti-PrP monoclonal antibody ICSM 35. (E, F) Hae-
matoxylin- and eosin-stained sections (H&E) showing
spongiform neurodegeneration including ﬂorid plaques in
vCJD prion-inoculated 129MM Tg35c mouse brain (inset).
Scale bars: A and B, 2 mm, C–F main panels 100 μm, inset
panel E, 50 μm.
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129M transgenic mice is not unusual, even when abundant abnormal
PrP deposition and high levels of type 4 PrPSc are present in the brain of
elderly mice [4,15]. Interestingly, the two clinically aﬀected mice seen
after challenge with prions from mouse ID 223157 (Table 2) showed no
detectable abnormal PrP deposition in brain by IHC (data not shown),
although both were positive for type 4 PrPSc when brain was examined
by immunoblotting.
Consistent with our ﬁndings in 129MM Tg35c mice, indicative of
transmission of vCJD prions, inoculum from mouse ID 223157 trans-
mitted poorly to 129VV Tg152c mice (Fig. 1, Table 2) with only 2 of 16
inoculated mice becoming infected (Table 2). Although the aﬀected
mice developed clinical disease after prolonged incubation periods and
propagated type 5 PrPSc in the brain (Fig. 5), no abnormal PrP de-
position was observed by IHC (data not shown), however, as discussed
above, this is not unusual for primary transmission of vCJD prions to
these mice.
In wild-type FVB/N mice, inoculum from mouse ID 223157 trans-
mitted infection to 10 of 20 inoculated mice and produced clinical prion
disease in 7 of the 10 aﬀected mice. The mean incubation period in
these mice was 561 ± 38 days (Table 2) (roughly 200 days longer than
that typically seen with vCJD patient brain isolates (Table 1) [2,15,32];
indicative of a lower vCJD prion titre in the inoculum). All aﬀected
mice propagated the characteristic diglycosylated-dominant PrPSc type
that is seen after transmission of vCJD prions from patient brain to the
same mice (Fig. 4) [2,15,32]. Abnormal PrP deposition was observed in
the brains of 2 of 5 aﬀected mice available for IHC analyses, and con-
sisted of patchy diﬀuse and granular deposits in the midbrain and
brainstem which closely resembled the pattern seen after transmission
of vCJD prions from patient brain to the same mice (Fig. 4).
Fig. 4. Immunoblot and immunohistochemical analyses of
prion transmissions to wild-type FVB/N mice. (A)
Immunoblot of proteinase-K digested 10% (w/v) brain
homogenates analysed by enhanced chemiluminescence
with anti-PrP monoclonal antibody ICSM 35. Lane 1,
clinically aﬀected FVB/N mouse inoculated with vCJD
prions from patient brain culled 253 days post-inoculation.
Lane 2, brain from a clinically aﬀected FVB/N mouse (ID
459514) inoculated with 129MM Tg35c-passaged ovine
BSE prions culled 603 days post-inoculation. (B, C)
Deposition of abnormal PrP in the midbrain of clinically
aﬀected FVB/N mice inoculated with either vCJD prions
from patient brain (B) or 129MM Tg35c-passaged ovine
BSE prions (C) stained with anti-PrP monoclonal antibody
ICSM 35. Scale bar; 100 μm.
Table 2
Transmission of 129MM Tg35c-passaged ovine BSE prions in transgenic and wild-type mice.
Mouse line Clinical attack ratea Incubation period (days ± SEM) Total attack rateb Survival (days)c
129MM Tg35c 2/19 513, 690 17/19 493, 513, 527, 598, 616–701 (15)d
129VV Tg152c 2/16 590, 688 2/16 449, 458, 579, 588, 590, 598, 616–701 (10)
FVB/N 7/20 561 ± 38 10/20 410, 431, 515, 529, 532, 580, 585, 603–701 (13)e
a All mice were inoculated with 30 μl of 1% (w/v) brain homogenate from 129MM Tg35c mouse ID 223157 (see Fig. 1). Clinical attack rate is deﬁned as the total number of clinically
aﬀected mice as a proportion of the number of inoculated mice. Incubation periods are reported for clinically aﬀected mice in days; where n≥ 3 the mean ± SEM is reported otherwise
individual incubation times are given.
b Total attack rate is deﬁned as the total number of clinically aﬀected and subclinically infected mice as a proportion of the number of inoculated mice. Subclinical prion infection was
assessed by immunohistochemical examination of brain for abnormal PrP deposition and immunoblot analysis of brain homogenate for PrPSc.
c The interval between inoculation and culling (due to clinical prion disease, inter-current illness, senescence, or termination of the experiment) in days. Death dates of individual mice
are shown together with the range for mice surviving beyond 600 days with the number of mice in this range shown in parentheses.
d Aﬀected mice were culled at 493, 513, 527, 598 and between 616–701 days post-inoculation.
e Aﬀected mice were culled at 410, 431, 532, 580 and between 603–701 days post-inoculation. Mice with clinical prion disease were culled at 410, 431, 580, 603, 610, 627 and
669 days post-inoculation.
Fig. 5. Molecular strain typing of 129MM Tg35c-passaged ovine BSE prion transmissions
to transgenic mice. (A, B) Immunoblots of proteinase-K digested 10% (w/v) brain
homogenates analysed by enhanced chemiluminescence with anti-PrP monoclonal anti-
body 3F4. The volumes of samples loaded were varied to give roughly equivalent levels of
total PrP signal intensity in each lane. (A) Brain from a clinically aﬀected 129MM Tg35c
mouse inoculated with vCJD prions from patient brain (culled 664 days post-inoculation)
is compared with brain from two subclinically aﬀected 129MM Tg35c mice inoculated
with 129MM Tg35c-passaged ovine BSE prions (ID numbers 444376 and 446497, both
culled 701 days post-inoculation). All three brain samples show the propagation of type 4
PrPSc (T4). Immunohistochemical analyses of brain from the same mice shown in lanes 2
and 3 are presented in Fig. 6. (B) Brain from a subclinically infected 129VV Tg152c mouse
inoculated with vCJD prions from patient brain (culled 687 days post-inoculation) is
compared to brain from a clinically aﬀected 129VV Tg152c mouse (ID number 448584)
inoculated with 129MM Tg35c-passaged ovine BSE prions (culled 590 days post-in-
oculation). Both brain samples show propagation of type 5 PrPSc (T5).
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4. Conclusions
Based upon the collective neuropathological and molecular pheno-
types observed in the secondary transmission series reported here, we
conclude that primary transmission of sheep BSE prions to 129MM
Tg35c mice led to the propagation of the vCJD prion strain. These data
concur with those of Torres and colleagues and strongly support their
proposal that small ruminant BSE prions might act as a causal agent of
vCJD [27]. This knowledge may have a future bearing upon under-
standing the zoonotic origin and epidemiology of vCJD and emphasizes
the importance of continued discriminatory TSE surveillance of small
ruminants within Europe [10,25].
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